AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.
Company Details
- Employees
- 23
- Address
- Nanna Svartz Väg 4, Innomedicum,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.anacardio.com
- Keywords
- Buddywise.
- HQ
- Solna, Stockholm County
Anacardio Questions
Anacardio's website is http://www.anacardio.com
Anacardio's LinkedIn profile is https://se.linkedin.com/company/anacardio
Anacardio has
23 employees.
View email and phone details for 23
employees at Anacardio.
Anacardio's industry is
Pharmaceutical Manufacturing
Anacardio's top competitors are
Qa.tech,
Moleculent,
Evroc,
Verdiva Bio,
Quartr,
Mynt,
Coave Therapeutics,
Buddywise,
Telness,
Insurely.
Anacardio's categories are Pharmaceutical Manufacturing
